Journal: Transplantation

Article Title: Urinary TIMP-2 Predicts the Presence and Duration of Delayed Graft Function in Donation After Circulatory Death Kidney Transplant Recipients

doi: 10.1097/tp.0000000000002472

Figure Lengend Snippet: FIGURE 2. TIMP-2 and IGFBP7 values were significantly different for patients with and without fDGF. Median ± IQR of both TIMP-2 and IGFBP7 are plotted for patients with and without fDGF. TIMP-2 values were significantly higher for patients with fDGF as compared to patients without fDGF (A). This also applied for the IGFBP7 values (B). Interestingly, TIMP-2 values of all patients decreased in the first 10 days after transplantation, where as IGFBP7 values increased. fDGF, functionally defined delayed graft function; IGFBP7, insulin-like growth factor-binding protein 7; IQR, interquartile range; TIMP-2, tissue inhibitor of metalloproteinases-2.

Article Snippet: Urinary TIMP-2 and IGFBP7 were quantified using sandwich immunoassays (ELISA, DTM200; R&D Systems, Minneapolis, MN for TIMP-2 and EK0991, Boster Biological Technology, Pleasanton, CA for IGFBP7, respectively) according to the manufacturer’s instructions.

Techniques: Transplantation Assay, Binding Assay

Journal: Transplantation

Article Title: Urinary TIMP-2 Predicts the Presence and Duration of Delayed Graft Function in Donation After Circulatory Death Kidney Transplant Recipients

doi: 10.1097/tp.0000000000002472

Figure Lengend Snippet: FIGURE 3. ROC curves of TIMP-2 and IGFBP7 in the prediction of fDGF and prolonged fDGF The absolute concentration of TIMP-2 on day 1 could adequately identify patients with fDGF, and this further improved in case TIMP-2 was corrected for osmolality (TIMP-2/ mOsm) (A). The concentration of IGFBP7 on day 1, on the other hand, showed only limited predictive value also when corrected for osmolality (IGFBP7/mOsm) (B). On day 10, both TIMP-2 and TIMP-2/mOsm could also adequately predict prolonged fDGF duration ≥21 days (C), whereas IGFBP7 and IGFBP7/mOsm could not (D). fDGF, functionally defined delayed graft function; IGFBP7, insulin-like growth factor-binding protein 7; ROC, receiver operating characteristic; TIMP-2, tissue inhibitor of metalloproteinases-2.

Article Snippet: Urinary TIMP-2 and IGFBP7 were quantified using sandwich immunoassays (ELISA, DTM200; R&D Systems, Minneapolis, MN for TIMP-2 and EK0991, Boster Biological Technology, Pleasanton, CA for IGFBP7, respectively) according to the manufacturer’s instructions.

Techniques: Concentration Assay, Binding Assay

Journal: Transplantation

Article Title: Urinary TIMP-2 Predicts the Presence and Duration of Delayed Graft Function in Donation After Circulatory Death Kidney Transplant Recipients

doi: 10.1097/tp.0000000000002472

Figure Lengend Snippet: FIGURE 5. TIMP-2/mOsm and IGFBP7/mOsm in tertiles. Patients were divided into tertiles based on TIMP-2/mOsm and IGFBP7/ mOsm concentrations, and the percentage of patients with fDGF and prolonged fDGF in each tertile was calculated. On day 1, patients without fDGF predominantly grouped together in the tertile with the lowest values for TIMP-2/mOsm, (77%), whereas patients with fDGF (92%) were in the middle or highest tertile (A). For IGFBP7/mOsm, a comparable figure was seen, with slightly lower percentages (B). On day 10, patients with prolonged fDGF predominantly grouped together in the tertile with the highest TIMP-2/mOsm values (83.3%), and none had TIMP-2/mOsm values in the lowest tertile (C). In contrast, patients with prolonged fDGF did not group together according to their IGFBP7/mOsm values (D). fDGF, functionally defined delayed graft function; IGFBP7, insulin-like growth factor-binding protein 7; TIMP-2, tissue inhibitor of metalloproteinases-2.

Article Snippet: Urinary TIMP-2 and IGFBP7 were quantified using sandwich immunoassays (ELISA, DTM200; R&D Systems, Minneapolis, MN for TIMP-2 and EK0991, Boster Biological Technology, Pleasanton, CA for IGFBP7, respectively) according to the manufacturer’s instructions.

Techniques: Binding Assay

Journal: The Journal of International Medical Research

Article Title: Upregulation of matrix metalloproteinase 9 (MMP9)/tissue inhibitor of metalloproteinase 1 (TIMP1) and MMP2/TIMP2 ratios may be involved in lipopolysaccharide-induced acute lung injury

doi: 10.1177/0300060520919592

Figure Lengend Snippet: Primer sequences for real-time quantitative polymerase chain reaction analyses.

Article Snippet: Mouse anti-rat MMP9 (cat. no. NBP2-13173SS) and TIMP2 antibodies (cat. no. NBP1-42375) were purchased from Novus Biologicals Inc. (Littleton, CO, USA).

Techniques: Real-time Polymerase Chain Reaction

Journal: The Journal of International Medical Research

Article Title: Upregulation of matrix metalloproteinase 9 (MMP9)/tissue inhibitor of metalloproteinase 1 (TIMP1) and MMP2/TIMP2 ratios may be involved in lipopolysaccharide-induced acute lung injury

doi: 10.1177/0300060520919592

Figure Lengend Snippet: Lung MMP and TIMP mRNA and protein expression. Changes in MMP2 (a), TIMP2 (b), MMP2/TIMP2 (c), MMP9 (d), TIMP1 (e), and MMP9/TIMP1 (f) in all groups treated with or without LPS. (g) Protein expression in each group as detected by western blotting. LPS 2h, 6h, 12h, and 24h indicate 2, 6, 12, and 24 hours after LPS injection in the acute lung injury group, respectively. Data are shown as mean ± standard deviation (n = 6 per group). * P < 0.05 vs. control, # P < 0.05 vs. LPS 2h. Control, normal control group; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase; LPS, lipopolysaccharide

Article Snippet: Mouse anti-rat MMP9 (cat. no. NBP2-13173SS) and TIMP2 antibodies (cat. no. NBP1-42375) were purchased from Novus Biologicals Inc. (Littleton, CO, USA).

Techniques: Expressing, Western Blot, Injection, Standard Deviation, Control

Journal: Cureus

Article Title: Abnormal Trophoblast Invasion in Early-Onset Preeclampsia: The Involvement of Cystathionine β-Synthase, Specificity Protein 1 and microRNA-22

doi: 10.7759/cureus.104353

Figure Lengend Snippet: mRNA expression of matrix metalloproteinases (MMPs) 2, 9 (a) and tissue inhibitors of metalloproteinase (TIMPs) 1, 2 (b) in the placental tissue samples from pregnancies complicated by early-onset preeclampsia (EOPE). Bar diagrams represent the relative mRNA expression of MMPs 2, 9 (a) and TIMPs 1,2 (b) in placentae from EOPE and normotensive, non-proteinuric controls. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a positive control. Data presented as mean ± SEM. Wilcoxon matched-pairs signed rank (MMPs 2, 9, TIMP-1) and paired t (TIMP-2) tests were applied, *p≤0.05 was considered statistically significant, *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001, ns: not significant.

Article Snippet: Primary antibodies to MMP-2 (Abcam) at a dilution of 1:500, MMP-9 (Abcam) at a dilution of 1:500, TIMP-1 (Thermo) at a dilution of 1:100, TIMP-2 (Novus Biologicals) at a dilution of 1:100, CBS (Abcam) at a dilution of 1:400 and Sp1 (Merck) at a dilution of 1:250 were used.

Techniques: Expressing, Positive Control

Journal: Cureus

Article Title: Abnormal Trophoblast Invasion in Early-Onset Preeclampsia: The Involvement of Cystathionine β-Synthase, Specificity Protein 1 and microRNA-22

doi: 10.7759/cureus.104353

Figure Lengend Snippet: Protein expression of matrix metalloproteinases (MMPs) 2, 9, and their feedback inhibitor tissue inhibitors of metalloproteinase (TIMPs) 1, 2 as analysed by immunohistochemistry (IHC). Representative IHC images of placentae from early-onset preeclampsia (EOPE) (a, e, i, m) and normotensive, non-proteinuric controls (b, f, j, n) showing MMP-2, MMP-9, TIMP-1 and TIMP-2 localization in syncytiotrophoblasts, stromal component, and blood vessels. Positive controls for MMP-2 (human placenta (c)), MMP-9 (human spleen (g)), TIMP-1 (rat brain (k)) and TIMP-2 (human pancreas (o)). Negative controls for MMP-2 (d), MMP-9 (h), TIMP-1 (l) and TIMP-2 (p), Scale Bar: 50 µm.

Article Snippet: Primary antibodies to MMP-2 (Abcam) at a dilution of 1:500, MMP-9 (Abcam) at a dilution of 1:500, TIMP-1 (Thermo) at a dilution of 1:100, TIMP-2 (Novus Biologicals) at a dilution of 1:100, CBS (Abcam) at a dilution of 1:400 and Sp1 (Merck) at a dilution of 1:250 were used.

Techniques: Expressing, Immunohistochemistry

Journal: Cureus

Article Title: Abnormal Trophoblast Invasion in Early-Onset Preeclampsia: The Involvement of Cystathionine β-Synthase, Specificity Protein 1 and microRNA-22

doi: 10.7759/cureus.104353

Figure Lengend Snippet: Protein expression of matrix metalloproteinases (MMPs) 2, 9 and tissue inhibitors of metalloproteinase (TIMPs) 1, 2 as analysed by immunofluorescence (IF) in EOPE and normotensive controls. Representative IF images of placentae from EOPE and normotensive, non-proteinuric controls showing MMP-2 (a, c (FITC stained), b, d (merged)], MMP-9 (e, g (FITC stained), f, h (merged)), TIMP-1 (i, k (TRITC stained), j, l (merged)) and TIMP-2 (m, o (FITC stained), n, p (merged)) localization in syncytiotrophoblasts, stromal component and blood vessels. Nuclei were stained by 4′,6-diamidino-2-phenylindole (DAPI); Scale Bar: 50 µm, FITC: Fluorescein isothiocyanate, TRITC: Tetramethylrhodamine isothiocyanate.

Article Snippet: Primary antibodies to MMP-2 (Abcam) at a dilution of 1:500, MMP-9 (Abcam) at a dilution of 1:500, TIMP-1 (Thermo) at a dilution of 1:100, TIMP-2 (Novus Biologicals) at a dilution of 1:100, CBS (Abcam) at a dilution of 1:400 and Sp1 (Merck) at a dilution of 1:250 were used.

Techniques: Expressing, Immunofluorescence, Staining

Journal: Cureus

Article Title: Abnormal Trophoblast Invasion in Early-Onset Preeclampsia: The Involvement of Cystathionine β-Synthase, Specificity Protein 1 and microRNA-22

doi: 10.7759/cureus.104353

Figure Lengend Snippet: Immunoblot of matrix metalloproteinases (MMPs) 2, 9 (a, b) and tissue inhibitors of metalloproteinase (TIMPs) 1, 2 (c, d) in the placentae from early-onset preeclampsia (EOPE) as compared to normotensive, non-proteinuric control placentae. Representative images of immunoblot showing the protein expression of MMP-2 (a), MMP-9 (b), TIMP-1 (c) and TIMP-2 (d) in placental tissues of EOPE and normotensive, non-proteinuric controls. Bar diagrams represent the normalized values of MMPs 2, 9 (e) and TIMPs 1, 2 (f) with respect to β-actin (loading control). Data presented as mean ± SEM. Statistical analysis was done using the Wilcoxon matched-pairs signed rank (MMPs 2, 9, TIMP-1) and paired t (TIMP-2) tests; *p≤0.05 was considered statistically significant. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001, ns: not significant

Article Snippet: Primary antibodies to MMP-2 (Abcam) at a dilution of 1:500, MMP-9 (Abcam) at a dilution of 1:500, TIMP-1 (Thermo) at a dilution of 1:100, TIMP-2 (Novus Biologicals) at a dilution of 1:100, CBS (Abcam) at a dilution of 1:400 and Sp1 (Merck) at a dilution of 1:250 were used.

Techniques: Western Blot, Control, Expressing